

Type 2 diabetes together with the metabolic syndrome much affect the human health worldwide: 30% global epidemics. In 1931, Elliot P. Joslin wrote: "It is time to move on from diabetes coma to diabetes complications". Indeed, in 1999 AHA recognized diabetes as a cardiovascular disease. However, new threatening have emerged over the latest years. Thus, more that 50% of the deceased patients affected with the Alzheimer disease showed glycosylated proteins in their necropsies in hippocampal and non-hippocampal brain structures. Thus, a new concept of Diabetes, type 3 Diabetes?, is currently on going. Indeed, the underlying molecular mechanism of such epidemiological association it is almost unknown. On the other hand, patients undergoing a long-standing insulin treatment of their type 1 diabetes showed hyperplastic focus in their retinas, suggesting a hyperproliferative side effect by the chronic insulin treatment. Indeed, insulin resistance it is the earliest pathophysiological event of type 2 diabetes, wich it is associated to for a long while to a compensatory hyperinsulinemia. In 2010, a consensus was reached associating the hyperinsulinemia of the prediabetes or type 2 diabetic patients to an enhanced susceptibility to develop a gastrointestinal tumor.

[www.uimp.es](http://www.uimp.es)

#### INFORMACIÓN GENERAL

→ **Hasta el 10 de junio de 2016**

##### Santander

Campus de Las Llamas  
Avda. de los Castros, 42  
39005 Santander  
Tel. 942 29 87 00 / 942 29 87 10  
Fax 942 29 87 27  
informacion@sa.uimp.es

##### Madrid

C/ Isaac Peral, 23  
28040 Madrid  
Tel. 91 592 06 31 / 91 592 06 33  
Fax 91 592 06 40 / 91 543 08 97  
alumnos@uimp.es

##### Horario

de 9:00 a 14:00 h  
de 16:00 a 18:00 h (excepto viernes)

#### PLAZOS

→ **Plazo de solicitud de becas**

Hasta el día 16 de mayo, para los cursos que comiencen antes del 8 de julio de 2016

Hasta el día 13 de junio, para los cursos que comiencen a partir del día 11 de julio de 2016

→ **A partir del 13 de junio de 2016**

##### Santander

Palacio de la Magdalena  
39005 Santander  
Tel. 942 29 88 00 / 942 29 88 10  
Fax 942 29 88 20

##### Horario

de 9:00 a 14:00 h  
de 15:30 a 18:00 h (excepto viernes)

→ **Apertura de matrícula**

Desde el 25 de abril de 2016  
(Plazas limitadas)

\* Curso acreditado por el Ministerio de Educación, Cultura y Deporte para profesores de enseñanzas no universitarias

Transporte oficial



→ Código 630B | Tarifa: A | ECTS: 0,5

@cursosUIMP

fb.com/uimp20



**UIMP**

Universidad Internacional  
Menéndez Pelayo

## Santander 2016

### Encuentro

### New complications of the diabetic syndrome in the new millenium: Type 3 Diabetes?

Manuel Benito

Santander

Del 7 al 9 de septiembre de 2016

[www.uimp.es](http://www.uimp.es)

NIPC: 041-16-002-1

**New complications of the diabetic syndrome in the new millenium: Type 3 Diabetes?****Dirección****Manuel Benito**PhD. DPhil. Complutense University & CIBERDEM (ISCIII)  
Madrid, Spain**Del 7 al 9 de septiembre de 2016****Miércoles 7**

15:30 h | Opening remarks

A. Insulin resistance as the initial pathophysiological feature in type 2

15:45 h | **Multiple Roles and Mechanisms Underlying Insulin Resistance in the Metabolic Syndrome****CR Kahn**Chief Academic Officer, Joslin Diabetes Center  
Mary K. Iacocca Professor, Harvard Medical School. Boston, U.S.A.16:45 h | **The adipose organ: A source of insulin resistant signals****Ulf Smith**MD, PhD. Professor of Medicine  
University of Gothenburg  
Sweden17:45 h | **Skeletal muscle insulin sensitivity****Anna Krook**Professor. Department of Physiology and Pharmacology Karolinska Institute  
Stockholm, Sweden**Jueves 8**

B. Elastoplasticity of pancreatic endocrine cells: The tipe 2 diabetes progression

10:00 h | **Molecular basis and regulatory networks of the pancreatic beta cell fate****Lorenzo Pasquali**

MD, PhD Germans Trias i Pujol Research Institute

11:00 h | **Failure of the compensatory mechanisms of beta-cell insulin secretion: The crossroad of Autophaty/Apoptosis****Manuel Benito**12:00 h | **Concluding remarks and Discussion**C. **Type 2 diabetes and metabolic syndrome vascular complications**15:00 h | **Type 2 diabetes, metabolic syndrome and macrovascular complications****Cristina Rondinone**Vicepresident R&D  
Head Cardiometabolic Diseases iMED  
Medimmune/Astra-Zeneca  
USA16:00 h | **Diabetic nephropathy****Jesús Egido**Professor and Chairman, Department of Medicine, Autonomia University  
Chief, Division of Nephrology and Hypertension  
Director Renal, Vascular and Diabetes Research Lab. University Hospital  
Fundación Jimenez Diaz & CIBERDEM (ISCIII)  
Madrid, Spain17:00 h | **Neurodegeneration in diabetic retinopathy: Therapeutic implications****Rafael Simó Canonge**Head of Diabetes and Metabolism Research Unit  
Vall d'Hebron Research Institute  
Barcelona & CIBERDEM (ISCIII),  
Madrid, Spain18:00 h | **Concluding remarks and Discussion****Viernes 9**D. **Neurodegeneration and type 2 diabetes: Type 3 Diabetes?**09:00 h | **Molecular basis of neurodegeneration in the Alzheimer disease: The metabolic environment****Jesús Ávila**Associate Professor Ad Honorem CBMSO  
(CSIC-UAM)& CIBERNED (ISCIII)  
Madrid, SpainE. **Cancer susceptibility associated to insulin resistance and type 2 diabetes**10:00 h | **Type 2 diabetes, metabolic syndrome and cancer: The IGFI and insulin connection****Emily Gallagher**Assistant Professor of Medicine and Endocrinology  
Division of Diabetes, Endocrinology and Bone Diseases,  
Department of Medicine. Mount Sinai School of Medicine  
New York, USA11:00 h | **Concluding remarks and discussion**F. **Drugs Discovery: New therapeutics approaches**11:15 h | **Beyond glucose control: addressing diabetes associated comorbidities****Holger J. Gellermann**Dr. Medical Director  
Boehringer Ingelheim Spain12:15 h | **Closure remarks**